Home › NDC Lookup › Ingredients › Pravastatin Sodium › 69097-0788-05
⚪image loading
(from DailyMed)

Pravastatin Sodium 10 mg Tablet, 90-count — NDC 69097-788-05 (Billing 69097-0788-05)

by CIPLA USA INC. · 90 TABLET in 1 BOTTLE

This is a package of 90 tablets of Pravastatin Sodium 10 mg Tablet from CIPLA USA INC., marketed since Jun 2024 and currently FDA-listed; retail pharmacies pay about $0.0555 per tablet (NADAC).

NDC 69097-0788-05
🏷️ FDA NDC (as labeled) 69097-788-05 billing pads the product segment with a zero
This package
Contains90-count Cost per ea$0.0555 NADAC Per package$5.00 / 90 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.2728/unit · Part D plans $0.1412/unit — full pricing hub ↓
Product page 69097-0788-12 Also comes in: 500 tablets 69097-788-12
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 69097-788-05 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
69097 labeler · 788 product · 05 package
Package marketed since
Jun 1, 2024
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
90 EA per package
Barcode (UPC-A, from the NDC)
3 6909778805 6
Medicaid fills, this package
4,421 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Pravastatin Sodium (different manufacturers) — 5 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0350-2025
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0341-2025
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0349-2025
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0325-2025
Class II · Jun 28, 2024 — Failed Dissolution Specifications: results below specifications (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0612-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 69097-788-05
Product NDC 69097-788
11-digit billing NDC 69097078805
NCPDP billing unit EA — each (per item)
Application # ANDA077987
SPL Set ID 61857346-86ef-4414-875f-7c205dacf301
Established class (EPC) HMG-CoA Reductase Inhibitor
Mechanism of action Hydroxymethylglutaryl-CoA Reductase Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-06-01
Route ORAL
Dosage form TABLET
Substance PRAVASTATIN SODIUM
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 016366
GCN 48671
HICL code 006227
Ingredient (HICL) Pravastatin Sodium
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M4
Therapeutic class — intermediate (HIC2) Affect Blood Lipids/Sugar/Amino Acids
HIC3 code M4D
Therapeutic class — specific (HIC3) Antihyperlipidemic-Hmgcoa Reductase Inhib(Statins)
AHFS code 24:06.08.00
AHFS class Hmg-Coa Reductase Inhibitors
FDB label name PRAVASTATIN SODIUM 10 MG TAB
FDB brand name Pravastatin Sodium
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 016366
  • GCN: 48671
  • HICL (First Databank): 006227
  • AHFS class code: 24:06.08.00
Why two NDCs? The FDA registers this code as 69097-788-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 69097-0788-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name PRAVASTATIN SODIUM 10 MG TAB Ingredient Pravastatin Sodium
📖 What it is MedlinePlus · NLM

Pravastatin is used to reduce the risk of heart attack and stroke decrease the amount of cholesterol (a fat-like substance that can build up and clog blood vessels causing heart attack or stroke or other health conditions) Pravastatin is in a class of medications called HMG-CoA reductase inhibitors (statins). It works by slowing how much cholesterol your body makes. This lowers the amount of cholesterol that can build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It lowers cholesterol and triglycerides, and it helps reduce your risk of heart attack, stroke and other heart problems. It works best together with a cholesterol-lowering diet. So...
  • Take it by mouth once a day at whatever time suits you, with or without food. Try to take it at the same time each day. If you use cholestyramine or colestipol, take pravastatin at...
  • Most people tolerate it well. Some notice muscle or joint aches, nausea, diarrhea, headache or cold-like symptoms. These are usually mild and temporary.
  • Call promptly if you have muscle pain, tenderness or weakness that is unexplained or doesn't go away. Rarely, statins cause serious muscle breakdown that can harm the kidneys. Your...
📖 Read our full Pravastatin guide →
1
Nutrient depletion considerations

Pravastatin Sodium may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Pravastatin Sodium nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.056 $5.00 / 90 tablets
Medicaid paysCMS SDUD · 12 mo $0.2728 $24.55 / 90 tablets
Medicare drug plans payPart D · Q2 2026 $0.1412 $12.71 / 90 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.064 $0.056
▼ Down 14% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
69097-0788-05 You're viewing this 90 TABLET in 1 BOTTLE $0.0555 / ea $4.99 2024-06-01 — Active
69097-0788-12 69097-788-12 Main listing 500 TABLET in 1 BOTTLE $0.0555 / ea $27.75 2024-06-01 — Active

You're viewing the smallest of 2 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0555 NADAC).

This pack accounts for about 35% of this product's recent Medicaid fills; most go to the 500 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 90-count package — 90 tablet in 1 bottle.
How does this package differ from NDC 69097-0788-12?
Both are Pravastatin Sodium 10 mg Tablet — the drug itself is identical. This page's package is the 90-count one, while NDC 69097-0788-12 is the 500 tablets package.
What NDC number is used to bill for this package of Pravastatin Sodium 10 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Pravastatin Sodium 10 mg 00093-0771-10 Teva 1000 tablets $0.055 AB Discontinued —
Pravastatin Sodium 10 mg 00904-5891-61 Major 100 tablets $0.055 AB Availability likely —
Pravastatin Sodium 10 mg 16714-0558-01 NorthStar 90 tablets $0.055 AB Availability likely —
Pravastatin Sodium 10 mg 50268-0665-15 AvPAK 50 tablets $0.055 AB Availability likely —
Pravastatin Sodium 10 mg 60687-0886-01 American 100 tablets $0.055 AB Availability likely —
Pravastatin Sodium 10 mg 68462-0195-05 Glenmark 500 tablets $0.055 AB Availability likely —
Pravastatin Sodium 10 mgthis 69097-0788-05 CIPLA 90 tablets $0.055 AB Availability likely —
Pravastatin sodium 10 mg 84386-0031-90 Aurobindo 90 tablets $0.055 AB Availability likely —
Pravastatin Sodium 10 mg 16729-0008-15 Accord 90 tablets $0.058 AB FDA listed +4%
Pravastatin Sodium 10 mg 68180-0485-02 Lupin 500 tablets $0.071 AB Discontinued +29%
Pravastatin Sodium 10 mg 00615-8539-39 NCS 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 00615-8618-39 NCS 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 50090-1594-00 A-S 90 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 50090-3853-00 A-S 90 tablets — AB FDA listed —
Pravastatin sodium 10 mg 51407-0887-10 Golden 1000 tablets — AB FDA listed —
Pravastatin sodium 10 mg 55111-0229-01 Dr.Reddy's 100 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 55154-3350-00 Cardinal 10 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 60505-0168-01 Apotex 100 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 62135-0847-90 Chartwell 90 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 63629-8833-01 Bryant 90 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 63629-8904-01 Bryant 90 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 63629-8905-01 Bryant 1000 tablets — AB Discontinued —
Pravastatin Sodium 10 mg 63629-9162-01 Bryant 30 tablets — AB FDA listed —
Pravastatin sodium 10 mg 65862-0632-05 Aurobindo 500 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 67046-1518-03 Coupler 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 67046-1621-03 Coupler 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 68071-5001-03 NuCare 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 68071-5007-03 NuCare 30 tablets — AB FDA listed —
Pravastatin sodium 10 mg 68788-4059-03 Preferred 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 68788-8425-03 Preferred 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 69292-0101-10 Amici 1000 tablets — AB FDA listed —
Pravastatin sodium 10 mg 70377-0045-11 Biocon 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 70518-0549-00 REMEDYREPACK 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 71335-1243-01 Bryant 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 71335-2298-01 Bryant 1000 tablets — AB FDA listed —
Pravastatin sodium 10 mg 71335-2848-01 Bryant 90 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 72162-1706-03 Bryant 30 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 72162-1951-00 Bryant 1000 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 72189-0059-90 DIRECT 90 tablets — AB FDA listed —
Pravastatin Sodium 10 mg 82868-0104-30 Northwind 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Jun 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Pravastatin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCIPLA USA INC.
Application holderGLENMARK PHARMACEUTICALS LTD
FDA applicationANDA077987 (ANDA)
Labeler code69097
First marketedJun 2024
Product typeHuman Prescription Drug
Portfolio222 products on file

More NDCs from CIPLA USA INC. labeler code 69097

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
4.4K
Units reimbursed last 4 qtrs
166.8K
Gross reimbursed last 4 qtrs
$45.5K
Avg / prescription
$10.30
Avg / unit
$0.2728
Latest quarter Q1 2026
446Rx
Medicaid pays / ea
$0.2728
gross reimbursed
vs
NADAC / ea
$0.0555
acquisition cost
=
Spread
+$0.2173
+392% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
41% FFS 59% MCO
Fee-for-service · 1,801 Rx Managed care · 2,620 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: 882 units · 44.9 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 3,239 units · 56.5 per 100k residents MN Wisconsin: 3,273 units · 55.4 per 100k residents WI Michigan: 17,496 units · 174 per 100k residents MI New York: 12,699 units · 64.9 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 630 units · 19.6 per 100k residents IA Illinois: 6,945 units · 55.3 per 100k residents IL Indiana: 3,973 units · 57.9 per 100k residents IN Ohio: 8,184 units · 69.4 per 100k residents OH Pennsylvania: 7,089 units · 54.7 per 100k residents PA New Jersey: 7,383 units · 79.5 per 100k residents NJ Massachusetts: 897 units · 12.8 per 100k residents MA California: 31,436 units · 80.7 per 100k residents CA Utah: no data reported UT Colorado: 390 units · 6.6 per 100k residents CO Nebraska: no data reported NE Missouri: 2,924 units · 47.2 per 100k residents MO Kentucky: 14,311 units · 316 per 100k residents KY West Virginia: 5,460 units · 308 per 100k residents WV Virginia: 6,672 units · 76.5 per 100k residents VA Maryland: 2,603 units · 42.1 per 100k residents MD Connecticut: 1,410 units · 39.0 per 100k residents CT Rhode Island: no data reported RI Arizona: 299 units · 4.0 per 100k residents AZ New Mexico: 1,380 units · 65.3 per 100k residents NM Kansas: no data reported KS Arkansas: 3,988 units · 130 per 100k residents AR Tennessee: 3,576 units · 50.2 per 100k residents TN North Carolina: 7,288 units · 67.3 per 100k residents NC South Carolina: 2,262 units · 42.1 per 100k residents SC Delaware: 1,012 units · 98.2 per 100k residents DE Oklahoma: no data reported OK Louisiana: 1,937 units · 42.3 per 100k residents LA Mississippi: 328 units · 11.2 per 100k residents MS Alabama: no data reported AL Georgia: 2,160 units · 19.6 per 100k residents GA D.C.: no data reported DC Hawaii: 474 units · 33.0 per 100k residents HI Texas: 2,955 units · 9.7 per 100k residents TX Florida: 1,290 units · 5.7 per 100k residents FL
Units reimbursed · per 100k residents
4.0316
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 316 /100k
2 West Virginia 308 /100k
3 Michigan 174 /100k
4 Arkansas 130 /100k
5 Delaware 98.2 /100k
6 California 80.7 /100k
7 New Jersey 79.5 /100k
8 Virginia 76.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 tablets69097-0788-12 8,105 Rx · $97,833
90 tablets this page69097-0788-05 4,421 Rx · $45,516
Drug total (last 4 qtrs): 12,526 Rx · 652,236 units · $143,349 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Pravastatin Sodium — the program that covers self-administered drugs. 14 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Pravastatin Sodium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$31.8M
Claims incl. refills
2.1M
Beneficiaries
1.7M
Spend / beneficiary
$18.70
Spend / claim
$15.06
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 69097-0770-32 · Cipla 69097-0789-05 · CIPLA →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.